Mission and Milestones

Sequella intends to commercialize improved treatment paradigms for infectious diseases of epidemic potential. The company initiated its business model with tuberculosis (TB), a disease designated by the World Health Organization (WHO) to be a global health crisis. Although TB has a devastating profile that makes it an important first target of Sequella, U.S. citizens are exposed to a number of lethal viral, bacterial, and fungal agents. Based on the company’s versatile discovery approach and technology platforms, Sequella is also identifying and developing drug candidates for SARS, candidiasis, ulcers (Helicobacter pylori), and other diseases with known or potential infectious etiology (Crohn’s disease).

Effectively addressing the global TB epidemic with new and improved diagnostics and drugs will serve as proof-of-principle for Sequella platform technologies and treatment paradigms -- creating a business and drug development strategy for application to other infectious disease areas.

Every day we strive to find the right balance between compassion and competitiveness, short and long term value, commitment to self and to society.

Date	Event
1997	Incorporation in Delaware First sale of common stock, Founders ($560,000)
1998	Hires first employee, Leo Einck, Ph.D., President - First Angel financing ($960,000)
1999	Carol A. Nacy, Ph.D., named CEO - Awarded first (of 7) NIH Small Business Innovation Research Phase I grant Signed CRADA with NIH to discover new TB drugs Albert Einstein College of Medicine grants exclusive world-wide license to antibiotic sensitivity test
2000	Awarded $1.2 million NIH Challenge Grant for discovery of new TB drugs Japan BCG Laboratory grants exclusive world-wide license (excl. Japan) to diagnostic Patch Test for Active TB Raises $400,000 in equity sales in private placement financing
2001	MRC, UK grants exclusive world-wide license to the hsp65 DNA vaccine technology
2003	Receives first (of 4) NIH Small Business Innovation Research Phase II grants ($1.0 million) Receives first (of 2) NIH U01 Biodefense Research grants ($1.6 million) Hires EVP Business Development, Alan Klein, MBA
2004	Sankyo Co., Ltd. grants exclusive worldwide license to commercialize new antibiotics Initiation of clinical trials in South Africa for Patch diagnostic using recombinant protein
2005	Initiates clinical trials in Peru for Patch diagnostic Receives U.S. patent for TB Patch Diagnostic, and also granted nine ex-US country Patch patents Receives U.S. patent for Therapeutic Diamine Anti-Infective Compounds Raises $2 million in equity sales in private placement financing Licenses out veterinary TB diagnostic to ChemBio, Inc.
2006	Hires VP of Finance, Marty Zug, MBA - Names Dr. C. Budd Colby Chair of Scientific Advisory Board NIH grants exclusive world-wide commercialization license to SQ109 and related compounds Raises $4 million from equity sales in private placement financing Files first Investigational New Drug (IND) application with U.S. FDA for new diamine antibiotic SQ109
2007	FDA grants Fast-Track designation to SQ109 SQ109 Phase Ia clinical trial completed SQ109 receives European Union Orphan Product designation TB STAT-PAK, a rapid lateral-flow serological test for TB for veterinary applications that Sequella licensed to Chembio Diagnostic Systems, is approved for marketing U.S. Orphan Drug Status Granted for SQ-109 European Medicines Agency (EMEA) Orphan Drug Status granted for SQ-109 Selected to Present at BIO 2007 Completed pivotal trial for TB Patch in South Africa
2008	Selected to Present at BioSquare2008 Presenting Company at BioEurope2008

Sequella proprietary technologies address unmet needs of the global health marketplace. Similar to blockbuster therapeutics Gleevec and Herceptin, Sequella engineers diagnostics to detect the type and presence of disease, as well as new drugs that can be efficiently and effectively administered based on more accurate diagnosis. As its targeted indications affect worldwide populations, Sequella will work closely with global healthcare agencies for introduction of its products into all markets.